![136699-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136699-Thumbnail%20Image.png?versionId=GjI3qklHXyNC60P5PDeT66QeTbLfRXa1&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T144751Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=2ef038cab81c5e72776dc72864d3b8284058e2266bd560b1b108bb0452af6c48&itok=2xPveqje)
![136935-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136935-Thumbnail%20Image.png?versionId=aUTdk4C1pX6WU6pL2oGcmKifq.utONV9&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T062707Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=0582479c49cee588a92cd33827975848ece07cd8be233277cdc2019ef70ae3ae&itok=peuQNl6h)
The synergistic effects between Vorinostat and Tamoxifen observed through a phase II study on breast cancer patients resistant to hormone therapy may involve more than the modulation of ER-alpha to reverse Tamoxifen resistance in ERBC cells. RT-qPCR of genes expressed in Tamoxifen resistant cells, trefoil factor 1(TFF1) and v-myc avian myelocytomatosis viral oncogene homolog (MYC), were evaluated along with ESR1 and Diablo as a control. MYC was observed to have increased expression in the treated cells, whereas the other genes had a decrease in their expression levels after the cells were treated for 3 days with Vorinostat IC30 of 1 µM. As for targeting the AR, MCF7 Tamoxifen sensitive and resistant cells were not affected by the AR antagonists to determine an IC50. The cell viability for all MCF7 sub-clones only decreased for high concentrations of 5.56 µM - 50 µM in Bicalutamide and 16.67 µM – 50 µM of MDV1300. Furthermore, hormone depletion of MCF7 G11 Tamoxifen resistant sub-clones did not show a great response to DHT stimulation or the AR antagonists. In the RT-qPCR, the MCF7 G11 cells showed an increase in mRNA expression for ER, AR, and PR after 4 hours of treatment with estradiol. As for the DHT treatment, ER, AR, PR, and PSA had a minimal increase in the fold change, but the fold change in AR was less than in the estradiol treatment. The Mayo Clinic will investigate the possible usage of AR as a biomarker through immunohistochemistry.
![137139-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137139-Thumbnail%20Image.png?versionId=coFJjtYqhO_WYOhhb.7jurlC38C7aEVK&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240530/us-west-2/s3/aws4_request&X-Amz-Date=20240530T165241Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=7177a41998a1e846e15ce367e5c1e785a79e90aec790b014a9824a7ec271bb8c&itok=EILIMXs4)
![137083-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137083-Thumbnail%20Image.png?versionId=wfwp1XiFhndM_l_D6BlxiGxJKd_iCqnH&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T081554Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=7f1c0534365656ec070d32e6350caa77d0b178b9ed443b5a3019f0da3b259dcb&itok=QEGPPz4v)
![137735-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137735-Thumbnail%20Image.png?versionId=p0eXeP2d03kcFVsH6Euhiot_ftbbE3Gt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=59292f0c61db9dd0f6fad453682f193d9c2d7b6018f4a2523a3f13fdd50cecc3&itok=v4vqSaHP)
![137273-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137273-Thumbnail%20Image.png?versionId=Hu0K4Z1UUNTw5dQPNolgpjvNAy5jiqLb&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240606/us-west-2/s3/aws4_request&X-Amz-Date=20240606T101147Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=cda817c6ebc99ba1eabf93a5773e0c75d207e873997ad0f63b544588498d75ea&itok=E-z8Q_a2)
![137471-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/137471-Thumbnail%20Image.png?versionId=oBm7GR8SlMoe01GHGkxRpxffqdtTIygj&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240614/us-west-2/s3/aws4_request&X-Amz-Date=20240614T171244Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=4559ab9e0e7893b04a4275e191362932a202d2e816494fdfe5d803f01d33e3d3&itok=8MaqFm5-)
![136571-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-05/136571-Thumbnail%20Image.png?versionId=B_bmZ0K8fCXnwNcGlw_rvi7KyKtlyAbo&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240615/us-west-2/s3/aws4_request&X-Amz-Date=20240615T202724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5b3949d006bbdf5cf2c62b585b2759b527a29cd9e7b35db738f59734997844c5&itok=t-KZLV2M)
![130350-Thumbnail Image.png](https://d1rbsgppyrdqq4.cloudfront.net/s3fs-public/styles/width_400/public/2021-04/130350-Thumbnail%20Image.png?versionId=w3dG6iWiJ7Jasvugcwrgw.8FSiNaZnFt&X-Amz-Content-Sha256=UNSIGNED-PAYLOAD&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=AKIASBVQ3ZQ42ZLA5CUJ/20240605/us-west-2/s3/aws4_request&X-Amz-Date=20240605T170724Z&X-Amz-SignedHeaders=host&X-Amz-Expires=120&X-Amz-Signature=5f6a567148781deda2b2127cea49a69bf03bb9d1363d553f03ee72983f413f09&itok=D7ID6Po8)
The membrane proximal region (MPR, residues 649–683) and transmembrane domain (TMD, residues 684–705) of the gp41 subunit of HIV-1’s envelope protein are highly conserved and are important in viral mucosal transmission, virus attachment and membrane fusion with target cells. Several structures of the trimeric membrane proximal external region (residues 662–683) of MPR have been reported at the atomic level; however, the atomic structure of the TMD still remains unknown. To elucidate the structure of both MPR and TMD, we expressed the region spanning both domains, MPR-TM (residues 649–705), in Escherichia coli as a fusion protein with maltose binding protein (MBP). MPR-TM was initially fused to the C-terminus of MBP via a 42 aa-long linker containing a TEV protease recognition site (MBP-linker-MPR-TM).
Biophysical characterization indicated that the purified MBP-linker-MPR-TM protein was a monodisperse and stable candidate for crystallization. However, crystals of the MBP-linker-MPR-TM protein could not be obtained in extensive crystallization screens. It is possible that the 42 residue-long linker between MBP and MPR-TM was interfering with crystal formation. To test this hypothesis, the 42 residue-long linker was replaced with three alanine residues. The fusion protein, MBP-AAA-MPR-TM, was similarly purified and characterized. Significantly, both the MBP-linker-MPR-TM and MBP-AAA-MPR-TM proteins strongly interacted with broadly neutralizing monoclonal antibodies 2F5 and 4E10. With epitopes accessible to the broadly neutralizing antibodies, these MBP/MPR-TM recombinant proteins may be in immunologically relevant conformations that mimic a pre-hairpin intermediate of gp41.